Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea; Yonsei Liver Center, Severance Hospital, Seoul, Korea.
Department of Clinical Pharmacology, Yonsei University College of Medicine, Seoul, Korea; Clinical Trials Center, Severance Hospital, Seoul, Korea.
Clin Gastroenterol Hepatol. 2020 Dec;18(13):3043-3045.e1. doi: 10.1016/j.cgh.2019.09.038. Epub 2019 Oct 4.
The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB. Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti-HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells..
乙型肝炎免疫球蛋白（HBIG）治疗慢性乙型肝炎（CHB）的作用机制尚不完全清楚。日本的一项临床试验表明，HBIG 治疗可能使 CHB 患者受益。Lenvervimab 是由 GC Pharma（韩国龙仁）开发的一种重组单克隆 HBIG，它是从乙型肝炎疫苗增强的人血细胞中克隆的抗 HBs 丰富噬菌体展示文库中筛选出来的，并在中国仓鼠卵巢细胞中生产。
